Compare LESL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LESL | BLRX |
|---|---|---|
| Founded | 1963 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4M | 12.0M |
| IPO Year | 2020 | 2010 |
| Metric | LESL | BLRX |
|---|---|---|
| Price | $0.23 | $2.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $2.54 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 703.3K | 19.3K |
| Earning Date | 05-18-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,241,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.62 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $2.15 |
| 52 Week High | $12.53 | $4.56 |
| Indicator | LESL | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 22.51 | 41.19 |
| Support Level | N/A | $2.18 |
| Resistance Level | $0.59 | $2.51 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 4.46 | 0.00 |
Leslies Inc is a direct-to-consumer pool and spa care brand offering a comprehensive assortment of products, including chemicals, equipment and parts, cleaning and maintenance equipment, and safety, recreational, and fitness-related products. The company serves residential pool, residential spa, professional pool, and commercial pool consumers and markets its products through over 1,000 company-operated locations in 39 states and e-commerce websites, operating only in the United States. It operates mainly in the pool and spa aftermarket industry and offers regularly purchased, non-discretionary maintenance items, along with installation and repair services for pool and spa equipment.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.